comparemela.com

Latest Breaking News On - Corbus pharmaceuticals company profile - Page 1 : comparemela.com

Corbus Pharmaceuticals (NASDAQ:CRBP) Lowered to Sell at StockNews com

StockNews.com lowered shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) from a hold rating to a sell rating in a research report released on Saturday morning. A number of other brokerages have also recently issued reports on CRBP. Royal Bank of Canada assumed coverage on Corbus Pharmaceuticals in a research report on Monday, May 13th. […]

Corbus Pharmaceuticals (NASDAQ:CRBP) Raised to Hold at StockNews com

StockNews.com upgraded shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday morning. Separately, Oppenheimer upped their price objective on shares of Corbus Pharmaceuticals from $20.00 to $51.00 and gave the company an outperform rating in a research note on […]

Oppenheimer Raises Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $51 00

Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) had its price objective increased by Oppenheimer from $20.00 to $51.00 in a research note published on Monday, Benzinga reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock. Separately, StockNews.com started coverage on shares of Corbus Pharmaceuticals in a research report on Friday, January 26th. They […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.